振德医疗
(603301)
| 流通市值：62.24亿 | | | 总市值：62.24亿 |
| 流通股本：2.66亿 | | | 总股本：2.66亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,125,390,090.31 | 2,042,419,723.69 | 963,887,437.65 | 4,127,044,057.44 |
| 营业收入 | 3,125,390,090.31 | 2,042,419,723.69 | 963,887,437.65 | 4,127,044,057.44 |
| 二、营业总成本 | 2,833,455,972.78 | 1,832,891,465.75 | 870,157,936.8 | 3,740,278,482.27 |
| 营业成本 | 2,036,380,225.14 | 1,319,157,578.63 | 628,159,512.79 | 2,694,610,618.49 |
| 税金及附加 | 29,635,314.02 | 20,610,507.08 | 8,176,728.1 | 33,079,274.77 |
| 销售费用 | 260,251,647.85 | 178,665,100.37 | 88,962,815.87 | 381,254,617.46 |
| 管理费用 | 394,925,025.94 | 262,769,885.49 | 125,807,862.59 | 513,185,929.17 |
| 研发费用 | 98,872,971.89 | 62,452,317.21 | 29,493,825.79 | 138,946,513.09 |
| 财务费用 | 13,390,787.94 | -10,763,923.03 | -10,442,808.34 | -20,798,470.71 |
| 其中:利息费用 | 23,927,495.58 | 16,400,517.1 | 8,617,084.42 | 28,928,842.79 |
| 其中:利息收入 | 21,746,194.32 | 16,480,612.8 | 9,129,586.63 | 39,954,915.7 |
| 加:公允价值变动收益 | -2,915,353.67 | -926,628.78 | -1,841,014.94 | -21,064,791.18 |
| 加:投资收益 | 8,575,281.52 | 1,274,897.18 | 764,903.27 | 6,800,977.99 |
| 资产处置收益 | 99,294,084.87 | 87,995.24 | 308,314.22 | -15,964,582.18 |
| 资产减值损失(新) | -26,131,509.05 | -22,005,732.22 | -15,011,076.66 | -207,459,610.51 |
| 信用减值损失(新) | -9,965,400.43 | -9,397,417.34 | -3,881,072.47 | -1,803,497.87 |
| 其他收益 | 35,095,066.37 | 22,694,951.04 | 11,704,234.34 | 78,674,176.19 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 395,886,287.14 | 201,256,323.06 | 85,773,788.61 | 225,948,247.61 |
| 加:营业外收入 | 356,965.54 | 20,121.8 | 29,871.37 | 662,900.55 |
| 减:营业外支出 | 15,423,812.13 | 3,452,759.36 | 767,328.09 | 7,718,851.97 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 380,819,440.55 | 197,823,685.5 | 85,036,331.89 | 218,892,296.19 |
| 减:所得税费用 | 63,345,085.69 | 30,536,089.17 | 9,806,221.72 | 5,492,447.44 |
| 六、净利润 | 317,474,354.86 | 167,287,596.33 | 75,230,110.17 | 213,399,848.75 |
| 持续经营净利润 | 317,474,354.86 | 167,287,596.33 | 75,230,110.17 | 213,399,848.75 |
| 归属于母公司股东的净利润 | 307,460,239.15 | 161,109,105.3 | 73,397,631.01 | 198,399,010.76 |
| 少数股东损益 | 10,014,115.71 | 6,178,491.03 | 1,832,479.16 | 15,000,837.99 |
| (一)基本每股收益 | 1.15 | 0.6 | 0.28 | 0.74 |
| (二)稀释每股收益 | 1.15 | 0.6 | 0.28 | 0.74 |
| 八、其他综合收益 | 49,566,938.58 | 35,850,865.24 | 37,701,731.11 | 19,789,035.35 |
| 归属于母公司股东的其他综合收益 | 42,163,042.24 | 36,081,159.49 | 29,681,539.6 | 5,902,490.82 |
| 九、综合收益总额 | 367,041,293.44 | 203,138,461.57 | 112,931,841.28 | 233,188,884.1 |
| 归属于母公司股东的综合收益总额 | 349,623,281.39 | 197,190,264.79 | 103,079,170.61 | 204,301,501.58 |
| 归属于少数股东的综合收益总额 | 17,418,012.05 | 5,948,196.78 | 9,852,670.67 | 28,887,382.52 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |